| CIN | Cervical Intraepithelial Neoplasia |
|---|---|
| CIN | central inhibition; cervical intraepithelial neoplasia; chronic interstitial nephritis |
| CIN1, | CIN I cervical intraepithelial neoplasia, grade 1 (mild dysplasia) |
| CIN | 2, CIN II cervical intraepithelial neoplasia, grade 2 (moderate-severe) |
| CIN | 3, CIN III cervical intraepithelial neoplasia, grade 3 (severe dysplasia and carcinoma in situ) |
| VAIN | Vaginal Intraepithelial Neoplasia |
|---|---|
| AIN | Anal intraepithelial neoplasia |
| CIN 3 | Cervical Intraepithelial Neoplasia grade 3 |
| CIN III | Cervical intraepithelial neoplasia grade III |
| HGPIN | High grade prostatic intraepithelial neoplasia |
| cervical intraepithelial neoplasia | A term which describes precancerous changes to the epithelial cells lining the cervix. The diagnosis is made from the microscopic examination of a PAP smear acquired tissue specimen. Less than 5% of all PAP smears will show cervical dysplasia. The peak incidence is in women 25 to 35 years of age. Risk factors include multiple sexual partners, early onset of sexual activity (less than 18), early childbearing (less than 16) and past medical history of a sexually transmitted disease (for example genital warts, genital herpes, HIV infection). Treatment is based on the degree of dysplasia present, as judged by a pathologist. Treatments include cryotherapy and conisation. Origin: Gr. Plassein = to form (27 Sep 1997) |
|---|---|
| prostatic intraepithelial neoplasia | A premalignant change arising in the prostatic epithelium, regarded as the most important and most likely precursor of prostatic adenocarcinoma. The neoplasia takes the form of an intra-acinar or ductal proliferation of secretory cells with unequivocal nuclear anaplasia, which corresponds to nuclear grade 2 and 3 invasive prostate cancer. (12 Dec 1998) |
| hereditary benign intraepithelial dyskeratosis | An autosomal dominant condition consisting of white spongy lesions of the buccal mucosa, floor of the mouth, ventral lateral tongue, gingiva and palate. Transient gelatinous plaques form over the cornea, which may produce temporary blindness, hereditary benign intraepithelial dyskeratosis. Synonym: hereditary benign intraepithelial dyskeratosis. (05 Mar 2000) |
| squamous intraepithelial lesion | A general term for the abnormal growth of squamous cells on the surface of the cervix. The changes in the cells are described as low grade or high grade, depending on how much of the cervix is affected and how abnormal the cells are. Also called sil. (12 Dec 1998) |
| intraepithelial | Within the layer of cells that forms the surface or lining of an organ. (12 Dec 1998) |
| intraepithelial carcinoma | Cancer that involves only the cells in which it began and has not spread to other tissues. Lobular carcinoma in situ is found in the lobules of the breast. Ductal carcinoma in situ (also called intraductal carcinoma) arises in the ducts. (16 Dec 1997) |
| intraepithelial dyskeratosis | An autosomal dominant condition consisting of white spongy lesions of the buccal mucosa, floor of the mouth, ventral lateral tongue, gingiva and palate. Transient gelatinous plaques form over the cornea, which may produce temporary blindness, hereditary benign intraepithelial dyskeratosis. Synonym: hereditary benign intraepithelial dyskeratosis. (05 Mar 2000) |
| intraepithelial glands | Accumulations of glandular cells that lie within an epithelium, as those of the urethra. (05 Mar 2000) |
| multiple endocrine neoplasia | (type I) This is a hereditary disorder in which two or more of the following glands: parathyroid, pancreas, pituitary, adrenals or thyroid develop hyperplasia or a tumour. (type II) This is a hereditary disorder in which two or more of the following glands: thyroid, adrenal or parathyroid, develop overgrowth (hyperplasia) or malignant cells (cancer). The underlying cause is genetic and a positive family history for this illness is a risk factor. Incidence: approximately 3 in 100,000 people in the general population. Origin: Gr. Plassein = to form (27 Sep 1997) |
| multiple endocrine neoplasia 1 | <radiology> Multiple endrocrine neoplasia syndrome three P's. Pituitary adenoma, 65% can develop Cushing's, acromegaly, prolactinoma, parathyroid hyperplasia / adenoma, 88% can develop hyper-PTH pancreatic isleT-cell tumour, gastrinoma (Z-E) most common, 50% of Z-E can develop MEN-1, inconstant features: bronchial/intestinal carcinoid, thyroid adenoma, adrenal cortical tumour, lipoma, thymoma tissue expression Primary hyperparathyroidism (90%), Gastrinoma (30%), Prolactinoma (15%), Other (10%). Synonym: Wermer syndrome (12 Dec 1998) |
| multiple endocrine neoplasia 2 | <radiology> Multiple endocrine neoplasia syndrome, medullary thyroid carcinoma, usually multifocal; metastasis to local nodes, lung, liver, usually calcify in liver, pheochromocytoma, almost always bilateral, parathyroid hyperplasia, may be secondary to calcitonin secreted by medullary thyroid carcinoma inconstant feature: adrenal cortical hyperplasia Synonym: Sipple syndrome (12 Dec 1998) |
| multiple endocrine neoplasia 3 | <radiology> Multiple endocrine neoplasia syndrome (type 2B, type 3), medullary thyroid carcinoma, pheochromocytoma, marfanoid habitus (Cf: Marfan syndrome), mucosal neuromas, neurofibromas, ganglioneuromatosis coli More info: MEN syndrome 2B Synonym: Schimke, marfanoid syndrome (12 Dec 1998) |
| multiple endocrine neoplasia type 1 | A rare syndrome characterised by hyperplasia and/or neoplasms of the pituitary, parathyroid glands, and pancreatic islets. Hyperparathyroidism occurs in 90% of the cases and is usually the first manifestation of the syndrome. The most frequent pancreatic manifestation is gastrinoma typically leading to zollinger-ellison syndrome. The appearance of this condition has been limited to the loss of allelic heterozygosity at the 11q13 locus on the long arm of chromosome 11. Patients overall exhibit long survival times. Chemotherapy is rare and surgical management is generally dependent on the genetic expression in individual patients. (12 Dec 1998) |
| multiple endocrine neoplasia type 2 | <syndrome> This is a hereditary disorder in which two or more of the following glands: thyroid, adrenal or parathyroid, develop overgrowth (hyperplasia) or malignant cells (cancer). The underlying cause is genetic and a positive family history for this illness is a risk factor. Incidence: approximately 3 in 100,000 people in the general population. (27 Sep 1997) |
| multiple endocrine neoplasia type 2a | A type of multiple endocrine neoplasia characterised by a virtually 100% incidence of medullary thyroid carcinoma, a 50% incidence of pheochromocytoma, and a lesser incidence of parathyroid adenomas associated with hyperparathyroidism. The condition is always transmitted through autosomal dominant inheritance. Genetic testing can identify individuals with the trait in early infancy. Treatment is usually excision of the enlarged parathyroid glands. (12 Dec 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|